Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.

Offin M, Feldman D, Ni A, Myers ML, Lai WV, Pentsova E, Boire A, Daras M, Jordan EJ, Solit DB, Arcila ME, Jones DR, Isbell JM, Beal K, Young RJ, Rudin CM, Riely GJ, Drilon A, Tabar V, DeAngelis LM, Yu HA, Kris MG, Li BT.

Cancer. 2019 Aug 30. doi: 10.1002/cncr.32461. [Epub ahead of print]

PMID:
31469421
2.

Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.

Mondaca S, Offin M, Borsu L, Myers M, Josyula S, Makhnin A, Shen R, Riely GJ, Rudin CM, Ladanyi M, Yu HA, Li BT, Arcila ME.

Acta Oncol. 2019 Jul 26:1-6. doi: 10.1080/0284186X.2019.1645354. [Epub ahead of print]

PMID:
31347936
3.

A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.

Castellano GM, Aisner J, Burley SK, Vallat B, Yu HA, Pine SR, Ganesan S.

J Thorac Oncol. 2019 Jun 27. pii: S1556-0864(19)30495-2. doi: 10.1016/j.jtho.2019.06.015. [Epub ahead of print]

PMID:
31254668
4.

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, Rudin CM, Yu HA.

J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30466-6. doi: 10.1016/j.jtho.2019.06.002. [Epub ahead of print]

PMID:
31228622
5.

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.

Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00011. Epub 2019 May 10. No abstract available.

6.

Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology.

Brastianos P, Davies MA, Margolin K, Yu HA.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e59-e69. doi: 10.1200/EDBK_241345. Epub 2019 May 17.

PMID:
31099629
7.

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.

Drilon A, Schoenfeld AJ, Arbour KC, Litvak A, Ni A, Montecalvo J, Yu HA, Panora E, Ahn L, Kennedy M, Haughney-Siller A, Miller V, Ginsberg M, Ladanyi M, Arcila M, Rekhtman N, Kris MG, Riely GJ.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003665. doi: 10.1101/mcs.a003665. Print 2019 Apr.

8.

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD.

Ann Oncol. 2019 May 1;30(5):839-844. doi: 10.1093/annonc/mdz077.

PMID:
30847464
9.

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M.

J Thorac Oncol. 2019 May;14(5):802-815. doi: 10.1016/j.jtho.2018.12.038. Epub 2019 Mar 1.

PMID:
30831205
10.

Bacillus velezensis YC7010 Enhances Plant Defenses Against Brown Planthopper Through Transcriptomic and Metabolic Changes in Rice.

Harun-Or-Rashid M, Kim HJ, Yeom SI, Yu HA, Manir MM, Moon SS, Kang YJ, Chung YR.

Front Plant Sci. 2018 Dec 21;9:1904. doi: 10.3389/fpls.2018.01904. eCollection 2018.

11.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV.

J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14.

PMID:
30550363
12.

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT.

J Natl Cancer Inst. 2018 Nov 28. doi: 10.1093/jnci/djy156. [Epub ahead of print]

PMID:
30496436
13.

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.

Helman E, Nguyen M, Karlovich CA, Despain D, Choquette AK, Spira AI, Yu HA, Camidge DR, Harding TC, Lanman RB, Simmons AD.

Clin Lung Cancer. 2018 Nov;19(6):518-530.e7. doi: 10.1016/j.cllc.2018.07.008. Epub 2018 Aug 7.

14.

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

Yu HA, Planchard D, Lovly CM.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:726-739. doi: 10.1200/EDBK_201331. Review.

PMID:
30231382
15.

ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers.

Fan PD, Yu HA.

Clin Cancer Res. 2018 Nov 15;24(22):5499-5501. doi: 10.1158/1078-0432.CCR-18-2179. Epub 2018 Aug 22.

PMID:
30135146
16.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6030-E6038. doi: 10.1073/pnas.1717782115. Epub 2018 Jun 6.

17.

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.

Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M.

Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12.

18.

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, Riely GJ, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4. No abstract available.

19.

Explosive detonation causes an increase in soil porosity leading to increased TNT transformation.

Yu HA, Nic Daeid N, Dawson LA, DeTata DA, Lewis SW.

PLoS One. 2017 Dec 27;12(12):e0189177. doi: 10.1371/journal.pone.0189177. eCollection 2017.

20.

Bioconverted Orostachys japonicas Extracts Suppress Angiogenic Activity of Ms-1 Endothelial Cells.

Lee SG, Kim JS, Lee HS, Lim YM, So JH, Hahn D, Ha YS, Nam JO.

Int J Mol Sci. 2017 Dec 5;18(12). pii: E2615. doi: 10.3390/ijms18122615.

21.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G.

Lung Cancer. 2017 Oct;112:195-199. doi: 10.1016/j.lungcan.2017.08.017. Epub 2017 Aug 23.

PMID:
29191595
22.

Development and Metabolite Profiling of Elephant Garlic Vinegar.

Kim JW, Jeong D, Lee Y, Hahn D, Nam JO, Lee WY, Hong DH, Kim SR, Ha YS.

J Microbiol Biotechnol. 2018 Jan 28;28(1):50-58. doi: 10.4014/jmb.1710.10002.

23.

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.

Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ.

Clin Cancer Res. 2018 Jan 15;24(2):334-340. doi: 10.1158/1078-0432.CCR-17-1841. Epub 2017 Oct 31.

24.

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR.

Clin Cancer Res. 2017 Dec 15;23(24):7467-7473. doi: 10.1158/1078-0432.CCR-17-1447. Epub 2017 Sep 27.

25.

Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.

Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA.

Cancer. 2018 Jan 1;124(1):105-109. doi: 10.1002/cncr.30990. Epub 2017 Sep 21.

26.

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Patel SH, Rimner A, Foster A, Zhang Z, Woo KM, Yu HA, Riely GJ, Wu AJ.

Lung Cancer. 2017 Jun;108:109-114. doi: 10.1016/j.lungcan.2017.03.010. Epub 2017 Mar 24.

27.

Detection of 2,4,6-Trinitrotoluene Using a Miniaturized, Disposable Electrochemical Sensor with an Ionic Liquid Gel-Polymer Electrolyte Film.

Yu HA, Lee J, Lewis SW, Silvester DS.

Anal Chem. 2017 Apr 18;89(8):4729-4736. doi: 10.1021/acs.analchem.7b00679. Epub 2017 Apr 4.

PMID:
28337908
28.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ.

Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.

29.

Investigating TNT loss between sample collection and analysis.

Nic Daeid N, Yu HA, Beardah MS.

Sci Justice. 2017 Mar;57(2):95-100. doi: 10.1016/j.scijus.2016.10.007. Epub 2016 Nov 5.

PMID:
28284444
30.

Fundamental studies of the adhesion of explosives to textile and non-textile surfaces.

Yu HA, Becker T, Nic Daeid N, Lewis SW.

Forensic Sci Int. 2017 Apr;273:88-95. doi: 10.1016/j.forsciint.2017.02.008. Epub 2017 Feb 17.

PMID:
28249217
31.

The stability of TNT, RDX and PETN in simulated post-explosion soils: Implications of sample preparation for analysis.

Yu HA, DeTata DA, Lewis SW, Nic Daeid N.

Talanta. 2017 Mar 1;164:716-726. doi: 10.1016/j.talanta.2016.07.001. Epub 2016 Jul 2.

PMID:
28107996
32.

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, Rudin CM, Kris MG, Pao W, Michor F, Riely GJ.

Ann Oncol. 2017 Feb 1;28(2):278-284. doi: 10.1093/annonc/mdw556.

33.

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Jakubowski CD, Plodkowski AJ, Chang JC, Rekhtman N, Iqbal A, Paik PK, Yu HA.

Clin Lung Cancer. 2017 Jan;18(1):e81-e83. doi: 10.1016/j.cllc.2016.10.001. Epub 2016 Oct 26. No abstract available.

34.

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.

Yu HA, Perez L, Chang Q, Gao SP, Kris MG, Riely GJ, Bromberg J.

J Thorac Oncol. 2017 Jan;12(1):102-109. doi: 10.1016/j.jtho.2016.08.140. Epub 2016 Sep 6.

35.

Association between depression and metabolic syndrome in korean women: Results from the korean national health and nutrition examination survey (2007-2013).

Park SJ, Roh S, Hwang J, Kim HA, Kim S, Lee TK, Kang SH, Ha YJ, Jang JW, Park S.

J Affect Disord. 2016 Nov 15;205:393-399. doi: 10.1016/j.jad.2016.08.022. Epub 2016 Aug 16.

PMID:
27588358
36.

The rs662 polymorphism of paraoxonase 1 affects the difference in the inhibition of butyrylcholinesterase activity by organophosphorus pesticides in human blood.

Nam DC, Ha YM, Park MK, Cho SK.

Int J Clin Pharmacol Ther. 2016 Aug;54(8):622-7. doi: 10.5414/CP202589.

PMID:
27087156
37.

Ecological niches and blood sources of sand fly in an endemic focus of visceral leishmaniasis in Jiuzhaigou, Sichuan, China.

Chen H, Li K, Shi H, Zhang Y, Ha Y, Wang Y, Jiang J, Wang Y, Yang Z, Xu J, Ma Y.

Infect Dis Poverty. 2016 Apr 13;5:33. doi: 10.1186/s40249-016-0126-9.

38.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.

Li BT, Lou E, Hsu M, Yu HA, Naidoo J, Zauderer MG, Sima C, Johnson ML, Daras M, DeAngelis LM, Fleisher M, Kris MG, Azzoli CG.

PLoS One. 2016 Jan 5;11(1):e0146063. doi: 10.1371/journal.pone.0146063. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0152450.

39.

Assessing a novel contact heater as a new method of recovering explosives traces from porous surfaces.

Yu HA, Lewis SW, Beardah MS, NicDaeid N.

Talanta. 2016 Feb 1;148:721-8. doi: 10.1016/j.talanta.2015.07.082. Epub 2015 Jul 29.

PMID:
26653508
40.

Pitavastatin Regulates Ang II Induced Proliferation and Migration via IGFBP-5 in VSMC.

Ha YM, Nam JO, Kang YJ.

Korean J Physiol Pharmacol. 2015 Nov;19(6):499-506. doi: 10.4196/kjpp.2015.19.6.499. Epub 2015 Oct 16.

41.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA.

Clin Cancer Res. 2016 Mar 1;22(5):1103-10. doi: 10.1158/1078-0432.CCR-15-1031. Epub 2015 Oct 7.

42.

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, Ladanyi M.

JAMA Oncol. 2015 Oct;1(7):982-4. doi: 10.1001/jamaoncol.2015.1066. No abstract available.

43.

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.

Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME, Yu HA.

Cancer. 2015 Sep 15;121(18):3212-3220. doi: 10.1002/cncr.29493. Epub 2015 Jun 10.

44.

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.

Riely GJ, Yu HA.

Clin Cancer Res. 2015 May 15;21(10):2221-6. doi: 10.1158/1078-0432.CCR-14-3154.

45.

Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals.

Kim SR, Ha YM, Kim YM, Park EJ, Kim JW, Park SW, Kim HJ, Chung HT, Chang KC.

Biochem Pharmacol. 2015 Jun 15;95(4):279-89. doi: 10.1016/j.bcp.2015.04.007. Epub 2015 Apr 17.

PMID:
25896849
46.

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ.

J Clin Oncol. 2015 May 20;33(15):1666-73. doi: 10.1200/JCO.2014.59.7328. Epub 2015 Apr 13.

47.

Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.

Yu HA, Sima CS, Hellmann MD, Naidoo J, Busby N, Rodriguez K, Riely GJ, Kris MG.

Cancer. 2015 Jun 15;121(12):2078-82. doi: 10.1002/cncr.29313. Epub 2015 Mar 17.

48.

Deer bone extract prevents against scopolamine-induced memory impairment in mice.

Du CN, Min AY, Kim HJ, Shin SK, Yu HN, Sohn EJ, Ahn CW, Jung SU, Park SH, Kim MR.

J Med Food. 2015 Feb;18(2):157-65. doi: 10.1089/jmf.2014.3187. Epub 2014 Dec 29.

49.

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ.

J Thorac Oncol. 2015 Mar;10(3):431-7. doi: 10.1097/JTO.0000000000000432.

50.

Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.

Yu HA, Riely GJ, Lovly CM.

Clin Cancer Res. 2014 Dec 1;20(23):5898-907. doi: 10.1158/1078-0432.CCR-13-2437. Epub 2014 Oct 10. Review.

Supplemental Content

Loading ...
Support Center